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1. Introduction
Teixobactin as one of very few new antibiotics against
multidrug resistant bacteria discovered in the recent decades has 
aroused extensive interests. It has a novel structural motif with a 
unique mode of action against Gram-positive bacteria and 
Mycobacterium tuberculosis, by interacting with the highly 
conserved motif of lipid II (precursor of peptidoglycan) and lipid 
III (precursor of the teichoic acid).1,2 Several research groups 
including us have devoted a lot of efforts on its total synthesis 
and analogue synthesis, with an ultimate goal of establishing the 
structure-activity relationship and of searching for teixobactin 
analogues with improved antimicrobial activity and 
pharmacological properties.3-10  
The primary structure of teixobactin contains a13-membered 
depsipeptide ring composed of 4 amino acids with a non- 
proteinogenic enduracidine (L-allo-End). An exocyclic tail is 
composed of 7 amino acid linear chain (Figure 1). Two 
independent total syntheses of teixobactin have been reported by 
Payne’s group4 and our group in 20165, of which our total 
synthesis featured a convergent strategy 6+7 via chemoselective 
Ser/Thr ligation11-13, which would be advantageous for the 
combinatory synthesis of its analogues. Herein, we reported our 
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Convergent Ser/Thr ligation has been used to prepare a series of teixobactin analogues (28 in 
total) to establish a structure-activity relationship of teixobactin. Anti-bacterial evaluations of 
these synthetic analogues have revealed the critical amino acid residues and the sites tolerable of 
modifications. These studies will shed lights on the further development of teixobactin 
analogues with improved antibacterial activities.  
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Figure 1. The structures of Teixobactin and its analogues.
structure-activity relationship studies of synthetic teixobactin 
analogues, via ligation-based synthetic strategies.  
 One objective of the teixobactin development as new 
antibiotics is to search for a simplified structure, which is 
amenable to large-scale preparation via chemical synthesis. To 
the end, identification of an effective  isostere of L-allo-
enduracidine (End) will be of importance, because the 
preparation of End represents a challenge for large-scale 
synthesis. Albericio et al first reported that teixobactin analogue 
with Arg to replace End could maintain good antibacterial 
activities.3 Several others have confirmed this finding6-10, while 
replacement with His caused significant decrease in the 
antibacterial activity.10 In our effort, we probed to use L-Orn and 
L-Norarginie as the isosteres of L-allo-End.
2. Results and discussion
Scheme 1. Synthesis of Orn10-teixobactin. 
We synthesized all the analogues with our previous serine 
ligation-mediated convergent 6+5 strategy with some 
modifications. Previously, the linear hexapeptide (1-6) fragment 
containing C-terminal salicylaldehyde ester which is requisite for 
Ser/Thr ligation was synthesized by Boc-solid phase peptide 
synthesis (Boc-SPPS), in which ozonolysis was needed to 
convert the alkenyl amide linker into the salicylaldehyde 
moiety.14 However, this method was not compatible with Met, 
Cys and Trp residues.  In this study, we adopted the “n+1” 
strategy recently developed by us15 to prepare the necessary 
peptide salicylaldehyde esters. To this end, the linear 
pentapeptide (1-5) was prepared by Fmoc-SPPS from a 2-
chrorotrityl chloride resin. After the synthesis, the side-chain 
protected peptide was cleaved from the resin with the mild acidic 
condition of trifluroethanol(TFE)/CH2Cl2/AcOH, which was 
subsequently elongated with Ile-salicylaldehyde semicarbazone 
ester 2 using EDC/HOOBt as the coupling reagents in 
CHCl3/TFE, under which condition no epimerization was 
observed.15 Next, the global deprotection of the obtained crude 
peptide with TFA/pyruvic acid afforded the side-chain 
unprotected peptide salicylaldehyde ester in 43% yield after 
HPLC isolation. Using this strategy, 20 hexapeptide derivatives 
with variations of amino acid residues at different positions (1-6) 
have been prepared with approximate 40%~50% yields.  
Seven different cyclic pentapeptide fragments were 
synthesized according to the previous strategy.5 The linear 
peptides were then ligated with the cyclic fragment in 
pyridine/AcOH (mole: mole, 6:1), followed by acidolysis. All the 
ligations proceeded smoothly with completion in 12 hours and 
afforded the teixobactin analogues in approximate 30%~50% 
yields after HPLC purification. All the obtained teixobactin 
analogues have been characterized by ESI-MS.  
3. Biological studies
All the synthetic teixobactin analogues have been tested
against two Gram-positive gram pathogens, including 
methicillin-susceptible S. aureus strain ATCC29213 and a 
methicillin-resistant S. aureus clinical isolate. From these studies, 
we could see that Orn was an effective isostere of End with only 
4 fold decrease in its antibacterial activities. It was surprising to 
see that the antibacterial activity of NorgArg10-teixobactin 
decreased dramatically, as compared to the Arg10-teixobactin 
reported in the literature,3 because the difference between Arg 
and Norarginine is only one methene group. Thus, we focused on 
Orn10-teixobactin as  the starting point to establish its structure-
activity relationship.  
Table 1. MICs of teixobactin analogues in µg/mL. 
compounds MRSA SA SA86 ATCC29213 
T1  teixobactin 0.5 0.25-0.5 
T2 Orn-teixobactin (End10Orn) 2 2 
T3 teixobactin (End10NorArg) 16 8-16
T4 Orn-teixobactin NMeDPh1DPhe 16 16 
T5 Orn-teixobactin NMeDPhe1NMeLPhe ≥32 ≥32 
T6 Orn-teixobactin NMeDPhe1NMeDAla ≥32 ≥32 
T7 Orn-teixobactin Ile2Leu 4-8 4-8
T8 Orn-teixobactin Ile2Val 8-16 8 
T9 Orn-teixobactin Ile2D-alloIle ≥32 ≥32 
T10 Orn-teixobactin Ile2Ala ≥32 ≥32 
T11 Orn-teixobactin Ile2Thr ≥32 ≥32 
T12 Orn-teixobactin Ile2Phe ≥32 ≥32 
T13 Orn-teixobactin Ser3Ala 4 4 
T14 Orn-teixobactin Ser3Lys 8 4 
T15 Orn-teixobactin Ser3Asn ≥32 16 
T16 Orn-teixobactin DGln4LGln ≥32 ≥32 
T17 Orn-teixobactin DGln4DAsn 4 4 
T18 Orn-teixobactin D-alloIle5DVal 16 8-16
T19 Orn-teixobactin D-alloIle5DAla ≥32 ≥32 
T20 Orn-teixobactin Ile6Ala ≥32 ≥32 
T21 Orn-teixobactin Ile6Leu ≥32 ≥32 
T22 Orn-teixobactin Ile6Phe ≥32 ≥32 
T23 Orn-teixobactin Ile6Val ≥32 ≥32 
T24 Orn-teixobactin Ala9DAla ≥32 ≥32 
T25 Orn-teixobactin Ala9Gly ≥32 ≥32 
T26 Orn-teixobactin Ala9Phe ≥32 ≥32 
T27 Orn-teixobactin Ala9Orn 8 8 
T28 Orn-teixobactin Ile11Leu ≥32 ≥32 
T29 Orn-teixobactin Ile11Val 8 8 
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Along our synthesis of Orn-teixobactin analogues, we 
replaced NMeDPhe1, Ile2, Ser3, DGln4, D-alloIle5, Ile6, Ala9, Ile11 
with other amino acids including alanine and its structurally 
similar residue, respectively, to investigate the contribution of 
each amino acid upon its antibacterial activity. As seen from 
Table 1, substitution of NMeDPhe1 with DPhe (T4), NMeLPhe 
(T5), or NMeDAla (T6) in teixobactin resulted in analogues with 
impaired antibacterial activity suggesting that the both Phe 
residue and its N-methyl group were important for the activity 
probably due to its  stereochemistry and hydrophobicity. Ile2 
could tolerate some subtle structural variations such as Leu (T7) 
and Val (T8) (2-8 times higher in MICs), while changes of Ile2 to 
Phe (T12), Thr (T11), or Ala (T10) damaged all the activity. 
These data suggested that the residue with hydrophobic nature 
was the best fit for this position probably contributing to 
interaction with the membrane lipid. However, the residue with 
bulky hydrophobic side such as Phe might cause hindrance effect 
on this interaction. In addition, the chirality of amide of Ile2 was 
important for maintaining the interaction at this site since 
substitution with D-alloIle (T9) abolished the activity completely. 
Ser3 could be changed to Ala (T13) and Lys (T14), but not to 
Asn (T15), which indicated the size of the side chain of the 
amino acid was not critical at this position, while the nature of 
the side chain might be important. Change DGln4 to DAsn (T17) 
had little negative effect, but not to the stereoisomer LGln (T16). 
Replacement of D-alloIle5 with DVal (T18) and DAla (T19) 
demolished the activity. Ile6 is also critical for the antibacterial 
activity, because change to Ala (T20), Leu (T21), Phe (T22), or 
Val (T23) caused loss of all the activities. When Ala9 was 
changed to DAla (T24), Phe (T26), or Gly (T25), no activity was 
observed, but Ala9Orn analogue (T27) maintained the modest 
activity. That Ile11 could be replaced with Val (T29) but not with 
Leu (T28) indicated there likely exists a tight binding site (Table 
1).  
4. Conclusion
We have applied Ser/Thr ligation to synthesize 26 Orn10-
teixobactin analogues in a convergent synthetic manner. From 
our structure-activity relationship studies  and other reports,6-10 
we can learn that (1) the presence of D-amino acids in teixobactin 
(i.e., DPhe1, DGlin4, D-allo-Ile5)  and their stereochemistry are 
critical for teixobactin to process potent antibacterial activity, as 
replacing them with their L-isomer completely demolished the 
activity. (2) there appear some very tight interactions between 
teixobactin and its binding partner, since very subtle structural 
variation led to complete loss of the antibacterial activities (e.g., 
T21, T28) (2) it seems to be difficult to generate teixobactin 
analogues with improved activities just by simply swapping the 
amino acid residues present in teixobactin with other natural 
amino acids.  Teixobactin was produced by bacteria for their self-
defense purposes, which must have gone through the natural 
evolution and selection to produce the most optimal structure via 
choosing the most suitable natural amino acids and involving 
metabolic enzymatic transformations to convert 20 proteinogenic 
amino acids to D-amino acids and enduracidine. Thus, to develop 
teixobactin analogues with improved antibacterial activities and 
properties, one may need go beyond the natural amino acids 
replacement and make more dramatic changes. Furthermore, a 
clear understanding of the mechanisms of action will help the 
rational design and improvement.  
5. Experimental section
5.1 Chemistry 
All separations involved a mobile phase of 0.05% TFA (v/v) 
in acetonitrile (solvent A)/0.05% TFA (v/v) in water (Solvent B). 
HPLC separations were performed with a Waters HPLC system 
equipped with a photodiode array detector (Waters 2996) using a 
Vydac 218TPTM C18 column (5 µm, 4.6 x 250 mm) at a flow rate 
of 0.6 mL/min for analytical HPLC, Vydac 218TPTM column (10 
µm, 10 x 250 mm) at a flow rate of 4 mL/min for semi – 
preparative HPLC and Vydac 218TPTM column (10 µm, 22 x 250 
mm) at a flow rate of 10 mL/min for preparative HPLC. The
peptide synthesis was performed manually on 2-chlorotrityl
chloride Resin (resin loading: 0.4 mmol/g). Peptides were
synthesized under standard Fmoc/tBu protocols. The deblock
mixture was a mixture of 20/80 (v/v) of piperidine/DMF.
5.2 Synthesis of T2 Orn-teixobactin (End10Orn) 
5.2.1 Synthesis of the linear hexapeptide salicylaldehyde ester 4 
100 mg 2-chlorotrityl resin (0.5 mmol/g) was placed in a 6 mL 
polypropylene syringe with a polyethylene filter in the bottom. It 
was swollen with DCM for 1 hour. Then it was washed by DMF 
(3 × 2 mL) and DCM (3 × 2 mL). The first building block was 
added by using Fmoc-D-allo-Ile-OH (35.3 mg, 0.1 mmol) and 
DIEA (34.8 µL, 0.2 mmol) in 2 mL DCM and shook for 1 hour. 
Then 80 µL MeOH was added and shook for another 20 min. 
Then the resin was washed by DCM (3 × 2 mL) and DMF (3 × 2 
mL). The following amino acids were coupled through the 
general Fmoc-SPPS strategy. Then the resin was treated by a 
mixture of 3 mL DCM/AcOH/TFE (v/v/v=8:1:1) for 1.5 hours to 
obtain the crude linear peptide 3 (36.7 mg, 0.037 mmol). 
Boc-Ile-OH (1.4 g, 6.1 mmol) was dissolved in 10 mL 
anhydrous DCM. Then the mixture of compound 1 (0.5 g, 2.8 
mmol), EDCI(1.2 g, 6.1 mmol) and DMAP (3.6 mg, 0.3 mmol) 
in 20 mL anhydrous DCM was added to the solution and stirred 
at room temperature for 6 hours. The reaction mixture was 
washed by 1.0 M HCl (20 mL ×3) and brine (20 mL×3). The 
organic phase was dried with anhydrous Na2SO4 and 
concentrated under low pressure. The crude residue was purified 
by flash column chromatography on silica gel (hexanes: 
EtOAc=4:1) to afford compound 2 (0.8 g, 2.7 mmol, 44% yield). 
Compound 2 (0.3 g, 1.0 mmol) was dissolved in 2 mL 4N HCl 
solution (in dioxane) and stirred for 1 hour. The solution of HCl 
was blown away by a condensed air stream and residue was 
washed by ethyl ether (20 mL × 3). The crude residue was 
dissolved in CHCl3/TFE (v/v=3:1). Then compound 3 (0.3g, 0.3 
mmol), HOOBT (130.5 mg, 0.8 mmol) and EDC (46.6 mg, 0.3 
mmol) was added to the solution. The reaction mixture was 
stirred at room temperature for 6 hours. The mixture of 
CHCl3/TFE was blown away by a condensed air stream and 2 mL 
TFA/H2O (v/v=95:5) was added for 1hour. Then pyruvic acid 
(2.1 mL, 30.0 mmol) was added and stirred for another 2 hours. 
The mixture of TFA and pyruvic acid were blown away by a 
condensed air stream and residue was washed by ethyl ether (20 
mL × 3). The crude compound was dissolved in 10 mL 
H2O/CH3CN(v/v=1:1) and filtrated. The residue was purified by 
preparative HPLC (30-60% CH3CN/H2O over 30 min) to afford 
compound 4 (108.9 mg, 0.13 mmol, 43.3% yield). (ESI) m/z; 
calcd. for C43H64N7O10+ [M+H+] 838.5, found 838.2.   
5.2.2 Synthesis of T2 Orn-teixobactin (End10Orn) via serine 
ligation 
Compound 5 was synthesized by the method reported by our 
group.5 Compound 5 (1.8 mg, 3.8 µmol) and peptide SAL ester 4 
(4.7 mg, 5.7 µmol, 1.5 equiv) was dissolved in a mixture of 380 
µL pyridine/AcOH (mole/mole=6:1) and stirred at room 
temperature for 10 hours. After the solvent was removed by 
lyophilization, 1 mL TFA/H2O/TIPS (v/v/v=94:5:1) was added 
and stirred for 1 hour. TFA/H2O/TIPS was blown away by a 
condensed air stream. The residue was purified by preparative 
HPLC (20-60% CH3CN/H2O over 30 min) to afford compound 
T2 as a TFA salt (1.7 mg, 1.41 µmol, 36.8% yield). (ESI) m/z; 
calcd. for C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3 Synthesis of T3-29 Teixobactin analogues 
5.3.1 Synthesis of T3 Teixobactin (End10NorArg) via serine 
ligation 
Compound T3 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T3 as a 
TFA salt (1.8 mg, 1.46 µmol, 44.2% yield). (ESI) m/z; calcd. for 
C57H96N15O15+ [M+H+] 1230.7, found 1230.8.   
5.3.2 Synthesis of T4 Orn-teixobactin (NMeDPh1DPhe) via 
serine ligation 
Compound T4 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T4 as a 
TFA salt (2.0 mg, 1.68 µmol, 36.8% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.7.   
5.3.3 Synthesis of T5 Orn-teixobactin (NMeDPhe1NMeLPhe) via 
serine ligation 
Compound T5 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T5 as a 
TFA salt (1.8 mg, 1.49 µmol, 39.2% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.4 Synthesis of T6 Orn-teixobactin (NMeDPhe1NMeDAla) via 
serine ligation 
Compound T6 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T6 as a 
TFA salt (1.9 mg, 1.69 µmol, 44.5% yield). (ESI) m/z; calcd. for 
C51H92N13O15+ [M+H+] 1126.7, found 1126.6.   
5.3.5 Synthesis of T7 Orn-teixobactin (Ile2Leu) via serine 
ligation 
Compound T7 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T7 as a 
TFA salt (1.8 mg, 1.4 µmol, 39.4% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.6 Synthesis of T8 Orn-teixobactin (Ile2Val) via serine 
ligation 
Compound T8 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T8 as a 
TFA salt (1.7 mg, 1.4 µmol, 37.7% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.7.   
5.3.7 Synthesis of T9 Orn-teixobactin (Ile2D-alloIle) via serine 
ligation 
Compound T9 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T9 as a 
TFA salt (2.2 mg, 1.8 µmol, 47.4% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.8 Synthesis of T10 Orn-teixobactin (Ile2Ala) via serine 
ligation 
Compound T10 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T10 as a 
TFA salt (2.0 mg, 1.7 µmol, 44.7% yield). (ESI) m/z; calcd. for 
C54H90N13O15+ [M+H+] 1160.7, found 1160.7.   
5.3.9 Synthesis of T11 Orn-teixobactin (Ile2Thr) via serine 
ligation 
Compound T11 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T11 as a 
TFA salt (1.6 mg, 1.3 µmol, 34.2% yield). (ESI) m/z; calcd. for 
C55H92N13O16+ [M+H+] 1190.7, found 1190.6.   
5.3.10 Synthesis of T12 Orn-teixobactin (Ile2Phe) via serine 
ligation 
Compound T12 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T12 as a 
TFA salt (1.8 mg, 1.5 µmol, 38.3% yield). (ESI) m/z; calcd. for 
C60H94N13O15+ [M+H+] 1236.7, found 1236.7.   
5.3.11 Synthesis of T13 Orn-teixobactin (Ser2Ala) via serine 
ligation 
Compound T13 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T13 as a 
TFA salt (1.5 mg, 1.3 µmol, 33.3% yield). (ESI) m/z; calcd. for 
C57H96N13O14+ [M+H+] 1186.7, found 1186.6.   
5.3.12 Synthesis of T14 Orn-teixobactin (Ser2Lys) via serine 
ligation 
Compound T14 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T14 as a 
TFA salt (1.2 mg, 0.96 µmol, 25.4% yield). (ESI) m/z; calcd. for 
C60H103N14O14+ [M+H+] 1243.8, found 1243.9.   
5.3.13 Synthesis of T15 Orn-teixobactin (Ser2Asn) via serine 
ligation 
Compound T15 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T15 as a 
TFA salt (2.0 mg, 1.6 µmol, 42.8% yield). (ESI) m/z; calcd. for 
C58H97N14O15+ [M+H+] 1229.7, found 1229.7.   
5.3.14 Synthesis of T16 Orn-teixobactin (DGln4LGln) via serine 
ligation 
Compound T16 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T16 as a 
TFA salt (1.9 mg, 1.6 µmol, 41.6% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.7.   
5.3.15 Synthesis of T17 Orn-teixobactin (DGln4DAsn) via serine 
ligation 
Compound T17 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T17 as a 
TFA salt (1.7 mg, 1.4 µmol, 37.6% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.7.   
5.3.16 Synthesis of T18 Orn-teixobactin (D-alloIle5DVal) via 
serine ligation 
Compound T18 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T18 as a 
TFA salt (1.8 mg, 1.5 µmol, 39.9% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.8.   
5.3.17 Synthesis of T19 Orn-teixobactin (D-alloIle5DAla) via 
serine ligation 
Compound T19 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T19 as a 
TFA salt (2.0 mg, 1.7 µmol, 45.4% yield). (ESI) m/z; calcd. for 
C54H90N13O15+ [M+H+] 1160.7, found 1160.6.   
5.3.18 Synthesis of T20 Orn-teixobactin (Ile6Ala) via serine 
ligation 
Compound T20 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T20 as a 
TFA salt (1.8 mg, 1.6 µmol, 40.8% yield). (ESI) m/z; calcd. for 
C54H90N13O15+ [M+H+] 1160.7, found 1160.7.   
5.3.19 Synthesis of T21 Orn-teixobactin (Ile6Leu) via serine 
ligation 
Compound T21 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T21 as a 
TFA salt (1.9 mg, 1.6 µmol, 41.6% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.20 Synthesis of T22 Orn-teixobactin (Ile6Phe) via serine 
ligation 
Compound T22 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T22 as a 
TFA salt (2.2 mg, 1.8 µmol, 46.8% yield). (ESI) m/z; calcd. for 
C60H94N13O15+ [M+H+] 1236.7, found 1236.7.   
5.3.21 Synthesis of T23 Orn-teixobactin (Ile6Val) via serine 
ligation 
Compound T23 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T23 as a 
TFA salt (1.3 mg, 1.1 µmol, 28.8% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.6.   
5.3.22 Synthesis of T24 Orn-teixobactin (Ala9DAla) via serine 
ligation 
Compound T24 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T24 as a 
TFA salt (1.5 mg, 1.3 µmol, 34.2% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.23 Synthesis of T25 Orn-teixobactin (Ala9Gly) via serine 
ligation 
Compound T25 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T25 as a 
TFA salt (1.7 mg, 1.4 µmol, 36.8% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.7.   
5.3.24 Synthesis of T26 Orn-teixobactin (Ala9Phe) via serine 
ligation 
Compound T26 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T26 as a 
TFA salt (1.7 mg, 1.3 µmol, 35.0% yield). (ESI) m/z; calcd. for 
C63H100N13O15+ [M+H+] 1278.7, found 1278.8.   
5.3.25 Synthesis of T27 Orn-teixobactin (Ala9Orn) via serine 
ligation 
Compound T27 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T27 as a 
TFA salt (1.4 mg, 1.1 µmol, 29.6% yield). (ESI) m/z; calcd. for 
C59H101N14O15+ [M+H+] 1245.7, found 1245.7.   
5.3.26 Synthesis of T28 Orn-teixobactin (Ile11Leu) via serine 
ligation 
Compound T28 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T28 as a 
TFA salt (1.9 mg, 1.6 µmol, 41.6% yield). (ESI) m/z; calcd. for 
C57H96N13O15+ [M+H+] 1202.7, found 1202.8.   
5.3.27 Synthesis of T29 Orn-teixobactin (Ile11Val) via serine 
ligation 
Compound T29 was synthesized through the same method as 
compound T2. The residue was purified by preparative HPLC 
(20-60% CH3CN/H2O over 30 min) to afford compound T29 as a 
TFA salt (1.8 mg, 1.5 µmol, 39.8% yield). (ESI) m/z; calcd. for 
C56H94N13O15+ [M+H+] 1188.7, found 1188.6. 
5.4 Antibacterial studies 
Susceptibility to teixobactin and its analogues was tested on 
the selected Gram-positive strains using Tecan Freedom EVO 
high-throughput automated platform, following the standard 
broth dilution method as described by the Clinical and 
Laboratory Standards Institute. MICs were determined according 
to CLSI guideline.16 
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